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Aims: Atherosclerotic plaque development is accelerated in patients with diabetes. Bone marrow-derived
smooth muscle-like cells have been detected in neointima and diabetes has a numerical and functional
effect on circulating vascular progenitor cells. We hypothesized that an increased number of bone
marrow-derived smooth muscle-like cells correlates with accelerated atherosclerosis in diabetic
apoE-deﬁcient mice.
Methods: ApoE/mice were subjected to total body irradiation and transplanted with bone marrow cells
from GFP-transgenic mice. Mice were rendered diabetic by streptozotocin injection and examined after 4,
8, 11 and 15 weeks of diabetes.
Results: Diabetic mice showed a larger plaque area and a higher number of smooth muscle-like cells
compared to non-diabetic mice at 11 and 15 weeks after diabetes induction. Bone marrow-derived
smooth muscle-like cells were detected in atherosclerotic plaques of both diabetic and control mice,
but numbers were higher in plaques of diabetic mice 11 weeks after induction of diabetes. The higher
number of bone marrow-derived smooth muscle-like cells in plaque was associated with an increase in
in vitro differentiation of smooth muscle-like cells from spleen mononuclear cells in diabetic mice.
Conclusions: Diabetes increases the number of bone marrow-derived smooth muscle-like cells in
atherosclerotic plaques and the differentiation of mononuclear cells towards smooth muscle-like cells,
which may contribute to accelerated atherosclerotic plaque development in diabetic apoE/ mice.
 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Patients with diabetes are at a higher risk for developing
atherosclerosis than non-diabetic subjects and have enhanced
susceptibility for myocardial infarction, peripheral artery disease
and stroke [1]. Hyperglycemia, dyslipidemia and hypertension only
partly explain this increased incidence of macrovascular compli-
cations in diabetes [2]. Diabetes induces phenotypic changes in
vascular smooth muscle cells (SMC) such as increased contractility,
cellular proliferation, migration and extracellular matrix formation
[3], which may lead to accelerated SMC accumulation in athero-
sclerotic lesions [4]. The cellular and molecular mechanisms by: þ31 30 251 8328.
Verhaar).
er the Elsevier OA license.which diabetes accelerates atherosclerotic cardiovascular disease
are still poorly understood.
It has been hypothesized that bone marrow (BM)-derived
smooth muscle-like cells (SMLC) are involved in neointima
formation in various animal models of vascular diseases such as
postangioplasty restenosis, transplant-associated atherosclerosis,
and hyperlipidemia-induced atherosclerosis [5e8]. Whether or not
these BM-derived cells differentiate into vascular SMC has been
scrutinized in recent years [9]. An accumulating body of evidence
from genetic lineage tracing in several models of arterial injury
(mechanical injury, graft vasculopathy and chronic atherosclerosis)
now suggests that BM-derived SMLC are of monocyte/macrophage
lineage and may contribute to vascular remodeling and athero-
sclerosis in a paracrine fashion, but that it is unlikely that they
differentiate into a deﬁnitive smooth muscle cell lineage [10e14].
Interestingly, diabetes has a numerical and functional effect on
circulating vascular progenitor cells [15,16]. In human subjects,
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entiation, these cells could be characterized by positive staining for
CD14, CD105, and a-smooth muscle actin (a-SMA) and during
in vitro culture they developed additional SMC markers including
SM22a and calponin, but not smooth muscle myosin heavy chain
(SM-MHC) [17]. In another study, it was shown that peripheral
blood mononuclear cells (MNC) differentiated into PDGFR-
b expressing SMLC after stimulationwith TGF-b in vitro [18]. In type
2 diabetic patients, van Ark et al. observed a relative increase in
circulating (CD14þCD105þ) and cultured SMLC numbers compared
to endothelial progenitor cells [19]. We recently reported that
patients with type 1 diabetes have increased levels of collagen type
I- and a-smooth muscle actin (a-SMA)-positive SMLC/myoﬁbro-
blast progenitor cells after differentiation of peripheral blood MNC
in vitro [20]. In addition, we showed that SMLC differentiation was
accelerated and numeric outgrowth increased in diabetic mice [21].
The present study examined the role of BM-derived SMLC in
accelerated atherosclerosis in diabetic mice.We generated chimeric
mice by BM transplantation from green ﬂuorescent protein (GFP)-
transgenic mice into apoE-deﬁcient mice (GFPBM/apoE/) and
subsequently injected these mice with vehicle (control animals) or
streptozotocin (STZ) to induce diabetes. We hypothesized that an
increased number of BM-derived SMLC is present in diabetic
atherosclerotic plaques, which may correlate with accelerated
plaque growth in diabetic GFPBM/apoE/ mice.
2. Methods
A detailed description of the methods can be found in the
Supplemental material.
2.1. Animals and bone marrow transplantation
Male C57BL/6 apoE/ (n ¼ 63) and C57BL/6 GFP-transgenic
mice (strain name: C57Bl/6-Tg(UBC-GFP)30Scha/J; stock number:
004353) were obtained from Jackson Laboratories (Bar Harbor, ME,
USA). ApoE/ mice were lethally irradiated (700cGy) and rescued
by intravenous tail injection of 5  106 BM cells harvested from
femurs of age- and sex-matched GFPþmice (n ¼ 20). Normal chow
and water were given ad libitum. All procedures were approved by
the local ethical committee.
2.2. Induction of diabetes
At age 10e12 weeks, chimeric GFPBM/apoE/ mice were
randomly assigned to either the diabetic or non-diabetic control
group. Mice in the diabetic group were rendered diabetic by
a single intraperitoneal injection of streptozotocin (STZ) at a dose of
200mg/kg (Serva, Germany) in citrate buffer. Control mice received
citrate buffer alone. Non-fasting blood glucose levels were
measured within aweek after STZ injection and from then on every
4 weeks. Diabetic and control GFPBM/apoE/ mice were sacri-
ﬁced 4, 8, 11, and 15 weeks after induction of diabetes.
2.3. Blood sampling and tissue processing
After 4, 8, 11 or 15 weeks mice were anaesthetized by an
intraperitoneal injection (10 ml/g body weight) of ketamine (6 mg/
ml) andmedetomidine (50 mg/ml). Blood samples were obtained by
cardiac puncture. Perfusion of the arterial systemwas performed by
cardiac puncture with 0.9% NaCl, after which the aorta was har-
vested and snap-frozen in liquid nitrogen and stored at80 C. The
heart was stored overnight at 4 C in a solution containing 0.2%
paraformaldehyde and 4% sucrose to preserve the GFP ﬂuorescence
signal. This was followed by placing the heart in a 15% sucrosesolution before being embedded in TissueTek OCT (Sakura) and
frozen at 80 C for histological analysis. The spleenwas harvested
and used directly for cell culture studies.
2.4. Biochemical measurements
Blood glucose levels were measured using a portable glucose
meter (Medisense Precision Xtra; Abbott Laboratories, USA). Gly-
cated hemoglobin was measured in peripheral blood samples by
high-performance liquid chromatography. Total serum cholesterol
levels were measured according to manufacturer’s instructions
(Elitech CHOL-0420 kit, Bio-Rad). Stromal cell-derived factor (SDF)-
1a ELISA (R&D Systems) on plasma samples was performed
according to manufacturer’s instructions.
2.5. Immunohistochemical analysis
Serial 7 mm thick cross sections of the aortic sinus were stained
with Oil Red O and counterstained with hematoxylin-eosin to
measure atherosclerotic lesion area by image analyzing software
(Soft Imaging Systems, Germany). Stainings were examined with
light microscopy on the Olympus BX60 microscope by two
observers blinded to the identity of the samples.
2.6. Immunoﬂuorescence analysis
Double immunoﬂuorescence staining with antibodies directed
against a-GFP (Abcam), a-SMA (SigmaeAldrich), caldesmon (Santa
Cruz) and calponin (SigmaeAldrich) was performed using cross
sections of the aortic sinus. The nuclei were counterstained with
DAPI (Invitrogen). Single or double-positive cells were deﬁned as
nucleated cells staining positive for GFP (green), a-SMA, caldesmon
or calponin (red) or co-localization of GFP with one of the SMC
markers (yellow). The presence of double-positive cells was
conﬁrmed in a subset of the sections by z-axis images on the
confocal laser scanning microscope (LSM510). Macrophages were,
stained with rat-monoclonal MOMA-2 antibody (Millipore).
2.7. Smooth muscle-like cell culture and ﬂow cytometry
MNC were isolated from the spleen of apoE/ mice or diabetic
and control GFPBM/apoE/ mice and 5  106 MNC/well were
plated on ﬁbronectin-coated dishes in Dulbecco’s Modiﬁed Eagle
Medium (DMEM, Gibco) supplemented with 20% heat-inactivated
fetal bovine serum, antibiotics (penicillin 100U/ml and strepto-
mycin 100 mg/ml Invitrogen). When indicated, platelet-derived
growth factor (PDGF)-BB (5 ng/ml; R&D systems), transforming
growth factor (TGF)-b (5 ng/ml; R&D systems), or both were added
to the DMEM medium. After 3 or 7 days in culture, adherent cells
were washed with PBS and detached using trypsin-EDTA and a cell
scraper. SMLC were permeabilized, stained with a-SMA-FITC (R&D
Systems) and counted in a ﬂow cytometer (Beckman Coulter).
2.8. Real-time polymerase chain reaction
Real-time PCR was performed on cDNA from freshly isolated
spleenMNC and spleen-derived SMLC cultured for 4 or 8 days using
primers for a-SMA (mmActa2), calponin (mmCnn1), caldesmon
(mmCald1) and SM-MHC (mmMyh11). The expression values of the
genes of interest were normalized using the geometric average of
the expression values of 3 housekeeping genes, beta-actin
(mmActb), GAPDH (mmGapdh) and large ribosomal protein P0
(mmRplp0), and expressed as fold change relative to the spleen
MNC sample for each gene. Primer sequences are listed in
Supplemental Table I.
Fig. 1. Representative examples of oil red staining in aortic sinus from apoE/ mice
after 4 weeks (A) and after 15 weeks of diabetes (B), magniﬁcation 40. Quantiﬁcation
of lesion size in control (white bar) and diabetic (black bar) mice (C). *p < 0.05 versus
control (paired time point); #p < 0.05 versus 4 weeks.
Fig. 2. Examples of a-SMA (red) staining. Cell nuclei are blue (DAPI) (A, B). SMC
quantiﬁcation (C). Control mice, white bar; diabetic mice, black bar. Magniﬁcation 40,
inset 400. *p < 0.05 versus control (paired time point); #p < 0.05 versus 4 weeks;
$p < 0.05 versus 15 week controls.
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Data were analyzed in Sigmaplot by Student’s t-test or ANOVA,
and Student-Newman-Keuls method was used for comparisons of
group means. Logarithmic transformation was performed on the
number of cells in atherosclerotic plaques and on the number of
SMLC after culturing because of non-normal distribution of the
data. Data are expressed as mean  SEM. A value of p < 0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Characterization of the diabetic GFPBM/apoE
/ mouse model
3.1.1. BM transplantation
The degree of BM chimerism obtained by transplantation of
GFPþ BM to irradiated apoE/micewas assessed byﬂowcytometry
of peripheral blood leukocytes. The fraction of GFPþ peripheral
blood leukocytes in GFPBM/apoE/ mice 2 weeks after BM
transplantationwas 89 5%. At the time of sacriﬁce thiswas 90 3%
in control GFPBM/apoE/ mice and 86  6% in diabetic
GFPBM/apoE/mice, indicating successful long term replacement
of the hematopoietic stem cell population.
3.1.2. Effect of diabetes on metabolic parameters in GFPBM/
apoE/ mice
On a chow diet, a reduction in body weight was observed in
diabetic GFPBM/apoE/ mice at 4, 8, 11 and 15 weeks after dia-
betes induction compared to control GFPBM/apoE/mice. Plasma
glucose and glycated hemoglobin (HbA1C) were signiﬁcantly
higher in the diabetic mice compared to control mice at all time
points conﬁrming persistent hyperglycemia after STZ induction.
Furthermore, the induction of diabetes was associated with higher
total cholesterol levels after 4 and 11 weeks compared to control
mice (Supplemental Table II).
3.2. Diabetic GFPBM/apoE
/mice showacceleratedatherosclerosis
Induction of diabetes resulted in accelerated development and
progression of atherosclerosis. Larger plaques with a thickened
intima composed of a ﬁbrous cap and lipid-rich core were observed
in diabetic GFPBM/apoE/mice (Fig.1AeB). Oil RedO stainingwas
performed for the assessment of atherosclerotic lesion area at the
aortic sinus. In control GFPBM/apoE/ mice, we detected typical
ﬁbrous fatty streaks which signiﬁcantly increased in size over time
(Fig. 1C). Quantitative analysis of atherosclerotic lesions showed an
increase inplaque area over time. Furthermore, a signiﬁcantly larger
plaque areawas observed in diabeticmice compared to controlmice
at 8, 11 and 15 weeks after diabetes induction (Fig. 1C).
Immunoﬂuorescence staining for a-SMA was performed on
atherosclerotic lesions (Fig. 2AeB). a-SMAþ cells were present in
plaques of diabetic and control animals and localized predomi-
nantly in the media, the ﬁbrous cap and at the shoulders of the
atherosclerotic plaque. Quantitative assessment of the number of
a-SMAþ cells in the plaque showed signiﬁcant increase over time in
diabetic mice and not in control mice (Fig. 2C). The number of
a-SMAþ cells was higher in diabetic plaques at 11 and 15 weeks.
Comparing plaques of similar size from diabetic mice at 8 weeks
and control mice at 15 weeks showed signiﬁcantly more a-SMAþ
cells in the diabetic plaques.
3.3. GFPþ cells are present in neointima of atherosclerotic lesions
GFPþ cells were observed in plaques of control GFPBM/apoE/
mice as well as in diabetic GFPBM/apoE/mice at all time points.Most GFPþ cells were localized in the neointima and none were
detected in the media (Fig. 3A). Over time, the number of BM cells
did not increase in plaques of control mice. In diabetic plaques
there was an increase in GFPþ cells at 15 weeks compared to 4
weeks. Diabetic plaques contained higher numbers of GFPþ cells
compared to control plaques at 8, 11 and 15 weeks (Fig. 3B). In
Fig. 3. BM-derived cell quantiﬁcation. (A) Immunoﬂuorescent triple staining of aortic root section for GFP (green), a-SMA (red) and cell nuclei (blue, DAPI). (B) Quantiﬁcation of
GFP-positive cells in the plaques. Control mice, white bar; diabetic mice, black bar, magniﬁcation 40. (CeN) Representative immunoﬂuorescent stainings on aortic root sections
from diabetic or non-diabetic mice for a-SMA, Cnn1 (Calponin) or Cald1 (Caldesmon) (all red) co-stained with GFP (green) and cell nuclei (blue, DAPI). (O) Quantiﬁcation of a-SMA/
GFP double-positive cells and number of macrophages (P) in the plaques. Control mice, white bar; diabetic mice, black bar, magniﬁcation 40. *p < 0.05 versus control (paired time
point); #p < 0.05 versus 4 weeks; $p < 0.05 versus 15 week controls.
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GFPþ cells compared to similar sized control plaques at 15 weeks.
3.4. GFPþ/a-SMAþ and GFPþ/Cnn1þdouble-positive cells are
localized predominantly in the neointima
Double-staining for GFP with a-SMA, calponin or caldesmon
showed that only a few round, nucleated GFPþ cells in athero-
sclerotic lesions was positive for a-SMA or calponin, but not cal-
desmon (Fig. 3C,D and Supp Fig. IJ,N). Cells that were double-positive for GFP and a-SMA/calponin were localized predomi-
nantly in the neointima or on the luminal side of the vessel wall. In
the majority of plaques in diabetic and non-diabetic animals,
however, no evidence of double-positive cells could be found
(Fig. 3EeN). The observation that cells co-expressing GFP and
a-SMA/calponin were topologically and morphologically distinct
frommedial SMC, suggests that they are not differentiated SMC but
more closely resemble the proﬁle of the previously described
SMLC. We conﬁrmed the presence of double-positive cells by
using confocal microscopy (for movies of z-stack reconstructed
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literature [9].
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.atherosclerosis.2012.11.017.
3.5. Diabetes increases the amount of GFPþ a-SMAþ cells in
atherosclerotic lesions
We quantiﬁed GFPþ a-SMAþ cells in atherosclerotic plaques of
diabetic and control GFPBM/apoE/ mice (Fig. 3O). In control
mice, we found no signiﬁcant differences over time in the number
of plaque GFPþ a-SMAþ cells. Diabetic plaques showed an increased
amount of GFPþ a-SMAþ cells at 11 compared to 4 weeks after
diabetes induction. In addition, the number of GFPþ a-SMAþ cells
was higher in diabetic versus control plaques at 11 weeks, and
similar sized plaques from diabetic mice at 8 weeks and control
mice at 15 weeks showed a trend towards higher numbers of GFPþ
a-SMAþ cells in the diabetic mice. As only a part of the BM cells
could be characterized as a-SMAþ cells, we also determined the
number of macrophages in atherosclerotic plaques of control and
diabetic mice by MOMA-2 staining (Fig. 3P). Over time, we did not
observe any signiﬁcant differences in the number of MOMA-2þ
cells in neither control nor diabetic plaques. Macrophage content,
however, was higher in diabetic plaques at 8 and 15 weeks
compared to control plaques. Comparing similar sized plaques from
diabetic mice at 8 weeks and control mice at 15 weeks, no differ-
ence in the number of MOMA-2þ cells was detected.
3.6. Differentiation of MNC towards SMLC in vitro is increased in
diabetic apoE/ mice
Wepreviously described in vitro differentiation towards a-SMAþ
SMLC from spleen-derived MNC in DMEM culture medium sup-
plemented with 20% serum [21]. Under these conditions,
a proportion of spleen-derived MNC of untransplanted apoE/
mice became adherent to the culture dish, adopted an elongated
morphology after 8 days and expressed a-SMA (Supp Fig. IIAeD).
Interestingly, we detected a-SMA positivity by ﬂow cytometry in
a large fraction of native spleen-derived MNC, although a-SMA
signal intensity was lower than in SMLC and vascular SMC (Supp
Fig. IE).
In the present study, we compared the effect of adding PDGF-BB,
TGF-b or both to the DMEM culture medium on differentiation
towards SMLC. After 3 and 8 days of culture, cells were stained for
a-SMA and calponin. Adherent cells in all conditions stained posi-
tive for a-SMA and calponin as determined by immunoﬂuorescence
(Supp Fig. IIIAeP). At 8 days, a-SMA and calponin staining was
higher than at 3 days and most intense staining was seen in PDGF-
BB þ TGF-b conditions. Relative mRNA expression of a-SMA, cal-
ponin 1 and, caldesmon and SM-MHC was measured using semi-
quantitative PCR (Supp Fig. IV). After 3 days of culture, only
a-SMA and caldesmon were upregulated compared to pre-culture
apoE/ spleen MNC. After eight days of culture we observed
major upregulation of all 4 genes, reaching the highest levels with
the combination of PDGF-BB and TGF-b.
We next cultured spleen-derived MNC for 8 days in
DMEMþ PDGF-BB from control and diabetic GFPBM/apoE/mice
at 4 and 11 week time points. Numbers of a-SMAþ SMLC were
determined using ﬂow cytometry. There was no signiﬁcant differ-
ence over time in the number of a-SMAþ SMLC in control mice
(Supplemental Table III). In contrast, we observed a higher number
of SMLC at 11 weeks compared to 4 weeks after diabetes induction.
The number of SMLC cultured from diabetic mice was lower
compared to control mice at 4 weeks but signiﬁcantly higher at 11
weeks after diabetes induction. At all time points in both groups,the percentage of cultured spleen cells expressing GFP was high
(>70%), indicating that the majority of cultured a-SMAþ SMLCwere
BM-derived.
3.7. No differences in plasma SDF-1 levels of atherosclerotic mice
The chemokine SDF-1a is essential in stem cell mobilization,
homing and recruitment of smooth muscle progenitor cells to
neointimal hyperplasia [22]. Therefore, the levels of SDF-1a were
determined in peripheral blood of control and diabetic
GFPBM/apoE/ mice. We did not observe differences in plasma
SDF-1a levels between diabetic and control mice at any time point
(at 4 weeks 1.26  0.16 ng/ml in diabetic mice vs 1.09  0.27 ng/ml
in controls; at 11 weeks 1.34  0.10 ng/ml in diabetic vs
1.95  0.28 ng/ml in control mice).
4. Discussion
Vascular SMC play an important role in atherosclerotic plaque
development and progression, which is accelerated in diabetes. Our
data show that in a model of early stage atherosclerosis develop-
ment, a small amount of BM-derived SMLC is present in athero-
sclerotic plaques. Moreover, we report for the ﬁrst time that
diabetes not only increases the number of SMLC obtained in in vitro
culture from circulating MNC, but also enhances the amount of BM-
derived SMLC in the atherosclerotic plaque, which may contribute
to the accelerated atherosclerosis in diabetes.
The origin of neointimal SMC in atherosclerosis has been under
debate. Previously, the contribution of BM-derived SMC to neo-
intima formation in animal models of transplant arteriosclerosis
and mechanical vascular injury has been reported [5e7,12,13].
Fewer studies investigating the role of BM-derived SMC in
atherosclerosis have been published. In one study, BM-derived
a-SMAþ SMC were reported in atherosclerotic plaques of apoE/
mice fed a high fat diet for 8 weeks [6]. Similarly, Iwata et al.
recently demonstrated the presence of BM-derived a-SMAþ SMLC
in a BM transplant model in apoE/ mice on a high fat diet for 8
weeks [12]. In an elegant study by Yu et al., genetic lineage tracing
revealed that, although BM-derived SMC-like cells are infrequent in
advanced primary atherosclerotic plaques and absent in ﬁbrous
caps, these cells may secrete proinﬂammatory cytokines and
mitogens that promote local SMC proliferation and plaque growth
[14]. On the other hand, Bentzon and co-workers showed that, in
atherosclerotic plaques of apoE/mice that received BM from sex-
mismatched GFPþ apoE/ mice, not one single GFPþ a-SMAþ cell
was observed at 20 or 32 weeks of age [10].
We examined the contribution of BM-derived cells to plaque
development in irradiated apoE/ mice transplanted with GFPþ
BM on a normal chow diet which allowed investigation of the
origin of SMC found in early stage ﬁbrous plaques. In our model,
induction of diabetes by STZ administration caused markedly
accelerated atherosclerosis over time, with signiﬁcant increases in
plaque size in diabetic GFPBM/apoE/ mice compared to control
GFPBM/apoE/mice. Importantly, we show for the ﬁrst time that
the inﬂux of BM-derived GFPþ cells over time is increased in
atherosclerotic plaques from diabetic GFPBM/apoE/ mice
compared to control GFPBM/apoE/ mice. When we compare
plaques of similar size from diabetic apoE/ mice at 8 weeks and
from control apoE/ mice at 15 weeks, higher numbers of GFPþ
BM-derived cells are present in the diabetic atherosclerotic lesions.
Interestingly, this was associated with a higher number of a-SMAþ
cells but similar numbers of macrophages. Immunoﬂuorescent
stainings further revealed that there was a signiﬁcant increase in
the number of GFPþ a-SMAþ cells in diabetic plaques. In addition,
a higher fraction of spleen-derived MNC differentiated in vitro
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This latter observation is consistent with our previous human data
[20,21]. The increased amount of a-SMAþ cells in diabetic athero-
sclerotic plaques may (in part) be due to paracrine effects of BM-
derived SMLC by releasing cytokines and growth factors which
favor local SMC proliferation. Of note, injection of smooth muscle
progenitor cells obtained from healthy humans into apoE/ mice
can promote changes in plaque composition towards a more stable
phenotype, both during the development and the progression of
atherosclerosis [23]. This suggests suggest that circulating
progenitor cells have the potential to modulate atherosclerotic
plaque development which in a diabetic setting may result in
acceleration of disease through phenotypic changes in progenitor
cells.
Our study does not allow deﬁnitive conclusions on the mecha-
nism bywhich diabetes enhances the inﬂux of BM-derived SMLC in
the vascular wall. Previously, it has been reported that SDF-1a plays
an important role in neointima formation after vascular injury in
apoE/ mice by regulating neointimal SMC content [22]. A tran-
sient increase in plasma SDF-1a levels was observed after vascular
injury which was associated with an SDF-1aedependent recruit-
ment of circulating smooth muscle progenitor cells. We did not
observe any differences in SDF-1a plasma levels between control
and diabetic apoE/ mice at any of the time points. However, the
activity of dipeptidyl peptidase-4, for which SDF-1a is a substrate,
was reported to be increased in diabetes [24] and could therefore
have decreased the amount of plasma SDF-1a detectable by ELISA.
Therefore, we cannot exclude the possible effect of SDF-1a on
(BM-derived) SMLC mobilization and accumulation in diabetic
atherosclerotic plaques.
Likewise, circulating or local factors may inﬂuence the differ-
entiation of circulating MNC that enter the plaque. TGF-b was
shown to play a role in the transdifferentiation of vascular
progenitor cells towards a-SMAþ SMLC [18,25]. Under the stimulus
of TGF-b or PDGF-BB endothelial colony forming cells can trans-
differentiate into an SMC-like phenotype, both in vitro as well as
in vivo [26,27], and TGF-b promotes outgrowth of SMLC from
CD14þCD105þMNC in vitro [17]. We have not measured circulating
or vascular TGF-b levels in the present study. Interestingly though,
circulating levels of TGF-b were shown to be increased in diabetes
[28] and TGF-b levels were elevated in the aorta of diabetic apoE/
mice [29], suggesting that circulating vascular progenitors may
encounter these cytokines in the circulation or in the vascular wall.
In addition, we have previously reported increased expression of
TGF-b and decreased expression of BMP-6 in diabetic murine
cultured smooth muscle progenitor cells [21]. Such TGF-b/BMP-6
imbalance may be of consequence for the intimal lesions to which
progenitor cells home, both affecting transdifferentiation of
progenitor cells towards an SMLC phenotype, as well as affecting
resident cells by delivering TGF-b.
4.1. Study limitations
Our study employed lethal irradiation and reconstitution of
apoE/ BM with BM from GFP mice that have the normal apoE
genotype, which has been shown to have suppressive effects on
neointima formation in apoE/ mice [30]. In addition, we used
a-SMA to identify SMC as it is considered a sensitive marker for
SMC. However, a-SMA is not a deﬁnitive SMC lineage marker and
can be expressed by other cell types. Although we conﬁrmed the
presence of a-SMA- and calponin-positive cells by immunoﬂuo-
rescence in atherosclerotic plaques in a subset of tissue sections,
a limitation of our study is that we did not further characterize and
quantify SMC using speciﬁc markers such as SM-MHC, SM22a, and
smoothelin.5. Conclusion
Understanding the origin of SMC in diabetic atherosclerosis
development is necessary for improving therapeutic strategies to
control recruitment and accumulation of SMC in plaques. Further-
more, in the era of stem cell therapy, elucidating the effects of
diabetes on BM-derived cell differentiation and recruitment in
vascular disease may enhance its potential in a therapeutic setting.
Therapies aimed at enhancing vascular progenitor cell availability
in patients with ischemic cardiovascular disease are currently
receiving a lot of attention and various clinical trials have been
initiated. In patients with diabetes such therapeutic strategies may
stimulate pro-atherogenic and pro-ﬁbrotic processes due to altered
SMLC function.
In conclusion, we provide evidence that BM-derived SMLC may
be involved in early, rapid atherosclerosis development in diabetes
which is associated with increased circulating and plaque SMLC.
Future studies investigating the mechanisms underlying recruit-
ment, differentiation and paracrine activity of BM-derived cells
under diabetic conditions will further elucidate the involvement of
BM-derived cells in diabetic vascular disease and the consequence
this may have on the potential of stem cell therapy in patients with
diabetes.
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